lnsights into Adjuvant Systemic Treatment Selection for Patients with Stage III Melanoma: Data from the Dutch Cancer Registry-Reference-Cited by-同舟云学术

lnsights into Adjuvant Systemic Treatment Selection for Patients with Stage III Melanoma: Data from the Dutch Cancer Registry

Published:2024-08-24 Issue:5 Volume:19 Page:735-745
ISSN:1776-2596
Container-title:Targeted Oncology
language:en
Short-container-title:Targ Oncol

Author:

Aldenhoven Loeki^ORCID,van Weezelenburg Merel A. Spiekerman,van den Berkmortel Franchette W. P. J.,Servaas Nick,Janssen Alfred,Vissers Yvonne L. J.,van Haaren Elisabeth R. M.,Beets Geerard L.,van Bastelaar James

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s11523-024-01090-9.pdf

Reference42 articles.

1. Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472–92.

2. Testori AAE, Chiellino S, van Akkooi ACJ. Adjuvant therapy for melanoma: past, current, and future developments. Cancers (Basel). 2020;12(7):1994. https://doi.org/10.3390/cancers12071994.

3. Eggermont AMM, Chiarion-Sileni V, Grob J, Dummer R, Wolchok JD, Schmidt H, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16(5):522–30.

4. Eggermont AMM, Chiarion-Sileni V, Grob J, Dummer R, Wolchok JD, Schmidt H, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016;375(19):1845–55.

5. Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377(19):1824–35.